US-based antibiotics developer Oragenics has started dosing patients in a Phase II clinical trial of AG013 for the treatment of oral mucositis (OM).

AG013, a therapeutic candidate of ActoBiotics, is being developed as an oral rinsing solution to deliver Trefoil Factor 1 peptides to the mucosal tissues in oral cavity for protection against damage.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, placebo-controlled Phase II trial will investigate the efficacy, safety and tolerability of AG013 in approximately 200 patients at 30 centres in the US and Europe.

Intended to evaluate the investigational candidate’s ability to reduce the mucositis in subjects receiving chemo radiation for head and neck cancer, the trial will measure the duration, time to development and overall incidence of OM.

Oragenics president and CEO Alan Joslyn said: “We are very excited to dose the first patient and initiate the Phase II trial of AG013 for oral mucositis, one of the most common and debilitating complications of chemo-radiation therapies.

“With no approved preventative treatment, oral mucositis represents a serious unmet need that we hope to help overcome.”

“With no approved preventative treatment, oral mucositis represents a serious unmet need that we hope to help overcome.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is expected that the preliminary data from an initial 20 patients will be reported by the end of this year, while full results are anticipated by the end of next year.

Designed by the firm’s partner Intrexon, AG013 secured fast-track designation in November last year from the US Food and Drug Administration (FDA).

As per an exclusive channel collaboration agreement with Intrexon, Oragenics holds a worldwide licence for the development and commercialisation of AG013 for OM in cancer patients.